Preliminary results showed a small group of patients with CLL had 100% progression-free survival at 9.7 months when taking an investigational BCL2 inhibitor, sonrotoclax, with zanubrutinib.
Patients with chronic lymphocytic leukemia (CLL) taking a next-generation combination of a Bruton tyrosine kinase (BTK) inhibitor and a therapy to target the BCL2 protein had 100% progression-free survival (PFS) after 9.7 months, signaling what may be a treatment shift for this population, according to results reported Saturday at the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California.
Lead investigator Constantine Tam, MD, PhD, of St. Vincent’s Hospital, Melbourne, Australia, reported on results involving zanubrutinib, the second-generation BTK inhibitor sold as Brukinsa, and sonrotoclax, the investigational BCL2 inhibitor now being studied in several blood disorders. Both are made by BeiGene.
Advancing treatment options for patients with CLL or small lymphocytic lymphoma (SLL) is not just about finding new therapies for patients who relapse, but also keeping patients on therapy in the first place—and that may mean creating better, less toxic versions of what works.
Combing the BTK inhibitor ibrutinib with venetoclax, the BCL2 inhibitor, has been effective in clinical trials for patients with treatment naive CLL, but toxicity rates are high. A 2019 phase 2 study published in the New England Journal of Medicine showed high remission rates; however, 60% of the patients had grade 3 adverse events (AEs). In the 2022 CAPTIVATE trial, the grade 3 AEs for patients receiving a fixed-duration regimen ibrutinib and venetoclax were lower, but investigators reported that rates of diarrhea and neutropenia were “somewhat higher than expected with ibrutinib alone.”
Since then, the second-generation BTK inhibitor, zanubrutinib, has been approved for treatment of CLL, having demonstrated superior efficacy to ibrutinib in the head-to-head ALPINE trial with fewer cardiac effects. Now, a next-generation BCL2 inhibitor, sonrotoclax, is being studied with zanubrutinib in CLL, with preliminary results.
The ALPINE results make zanubrutinib "the natural partner to be chosen to be paired with the second-generation BCL2 inhibitor," Tam said.
Sonrotoclax is described as a BH3 mimetic with greater than 10-fold potency compared with venetoclax, with higher selectivity. Tam said it also has a shorter half-life than venetoclax, which makes it easier to develop a rapid dose escalation schedule.
The phase 1/2 BGB-11417-101 trial (NCT04277637) involves patients with treatment-naive CLL or small lymphocytic lymphoma; it is evaluating sonrotoclax as a monotherapy and in various combinations to determine efficacy and appropriate dosing for further study.
Based on the positive phase 1/2 results, BeiGene officials have said the 320 mg dose of sonrotoclax will be evaluated in a global phase 3 trial (NCT06073821).
Tam reported on the study arm involving 107 patients who were treated with the combination of sonrotoclax and zanubrutinib. In this arm, patients were treated with zanubrutinib monotherapy for 8 to 12 weeks before receiving sonrotoclax dosing; sonrotoclax was dosed orally, 30 minutes after a low-fat meal. A ramp-up schedule was used to reach a target dose.
In this arm, 51 patients received 160 mg and 56 received 320 mg of sonrotoclax, plus zanubrutinib. Slightly more than a third of the group were age 65 or older (39% of the 160 mg group, 34% of the 320 mg group). Roughly a quarter had high-risk clinical features, namely 17p deletion and/or TP53 mutation status (24% of the 160 mg group, 27% of the 320 mg group).
Results were as follows:
Selected AEs were as follows:
Investigators measured minimal residual disease (MRD), which showed a deepening response over time. By week 48, 100% of patients in the 320 mg group and 75% of patients in the 160 mg group had achieved undetectable MRD levels.
Reference
Tam CS, Anderson MA, Lasica M, et al. Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase Inhibitor, is well tolerated and achieves deep responses in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: data from an ongoing phase 1/2 study. Presented at: 65th American Society of Hematology Annual Meeting & Exposition; December 9-12, 2023; San Diego, California; Paper No. 0327. https://doi.org/10.1182/blood-2023-179541
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More